Treatment with Growth Hormone for Adults with Growth Hormone Deficiency Syndrome: Benefits and Risks.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
hypoglycemia 1 endocrinologydiseases
hypopituitarism 9 endocrinologydiseases
metabolic syndrome 1 endocrinologydiseases
obesity 2 endocrinologydiseases
Laron syndrome 1 endocrinologydiseases
acromegaly 3 endocrinologydiseases
cortisol 1 endocrinologydiseasesdrugs
glucose intolerance 2 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.


Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
cortisol 19573 Retinopathy and benign intracranial hypertension are very rare complications of GH treatment. The needs of cortisol and thyroxin may be increased in patients with hypopituitarism [[55]]. Special attention should be given
Select Disease Character Offset Disease Term Instance
Laron syndrome 33300 studies of GHR with variations in the coding region came from the work of Godowski et al. [[94]] on Laron syndrome , an autosomal recessive genetic disorder that is characterized by resistance to GH. The isoform of human
acromegaly 10388 with low QoL at baseline [[27],[28]].A special group consists of patients with a previous history of acromegaly who subsequently presents GHD. This particular group of patients exhibits a significant deterioration
acromegaly 24603 cancer incidence [[65],[66]], and the incidence of some malignant neoplasia is known to be increased in acromegaly [[67]]. Initial studies conducted in children treated with extractive GH showed an increased risk of
acromegaly 29882 was 1.27 (1.04–1.56) for the treatment group. This ratio was 1.29 (1.05–1.59) when patients with acromegaly and Cushing’s disease were excluded, and 1.00 (0.79–1.26) after the exclusion of high-risk patients
glucose intolerance 24333 with obesity or a family history of type 2 diabetes, because they are more prone to develop impaired glucose intolerance and diabetes during therapy [[64]].3.7. Risk of NeoplasiaEpidemiological studies have suggested an association
glucose intolerance 44960 modify blood glucose?Yes, in the long term blood glucose levels rise and in some cases the incidence of glucose intolerance and diabetes increasesDoes treatment during adult life increase the risk of cancer?Probably not, but
hypoglycemia 2823 axes is diagnostic of GHD. Expert consensus defines severe GHD as a GH response peak after insulin hypoglycemia below 3 μg/L. This is an arbitrary limit that depends on the assay method, the laboratory, and the
hypopituitarism 2469 lipid and carbohydrate metabolism. Its diagnosis is based on the combination of pituitary disease, hypopituitarism and a decrease in the concentration of insulin-like growth factor I (IGF-I) or in diminished GH responses
hypopituitarism 10890 has been considered the strongest contributor of the excess in cardiovascular risk associated with hypopituitarism [[31]]. Most studies have shown an increase in high-density lipoprotein (HDL) cholesterol and a decrease
hypopituitarism 14625 lipoprotein-cholesterol level, and these differences remained also after correction for duration of hypopituitarism . There was no difference at baseline or in responsiveness in lean mass, bone mineral density, and glucose
hypopituitarism 15619 with GHD [[42]].Retrospective [[43],[44]] and prospective [[45]] studies have shown that patients with hypopituitarism treated with usual replacement therapy without GH exhibit an increased mortality in comparison with
hypopituitarism 19629 complications of GH treatment. The needs of cortisol and thyroxin may be increased in patients with hypopituitarism [[55]]. Special attention should be given to older, heavier, and female patients with GHD because they
hypopituitarism 31626 Endocrine Society clinical practice guideline [[6]], although mortality is increased in patients with hypopituitarism and GHD has been implicated in this, there is no data to show that treatment with GH improves the survival
hypopituitarism 42244 treated with GH in childhoodMortalityTendency to decrease the global and cardiovascular mortality of hypopituitarism Persistence of higher mortality than the general population in some studiesAbbreviations: BMI, body mass
hypopituitarism 43897 not always referred in the studies5In the long-term results we must consider the effect of age and hypopituitarism 6In some studies follow-up is short to reach conclusive results on cardiovascular disease, neoplasia
hypopituitarism 45226 subgroups with higher risk of neoplasiaDoes treatment with GH decrease the mortality associated with hypopituitarism ?It has not been clearly demonstrated. In adult patients treated with GH, an increase in mortality persists,
metabolic syndrome 41638 insulin sensitivityIncrease in fasting glucose and insulinTrend to the increase in the prevalence of metabolic syndrome Increase in lipoprotein (a)Cardiovascular diseaseReduction in the incidence rate of myocardial infarctionTrend
obesity 12134 [[35]]. The study by Makimura et al. [[36]] is of particular interest in this context. In patients with obesity and decreased GH secretion, randomized and placebo-controlled administration of a GHRH analogue induced
obesity 24237 results [[63]].Close monitoring of glucose status is advisable during GH treatment in patients with obesity or a family history of type 2 diabetes, because they are more prone to develop impaired glucose intolerance

You must be authorized to submit a review.